[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580173":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":28,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Menarini Silicon Biosystems, INC","INDUSTRY",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"HR+\u002FHER2- subjects before starting 1st line therapy",null,"Subjects will receive CTC enumeration, CTC HER2, ER, PD-L1 expression and, and MSearch cfDNA\u002FRNA assessments at baseline and first restaging as part of standard of care. Subjects will have additional cfDNA\u002FRNA tests at week 4, and 8.",{"label":13,"type":10,"description":14,"interventionNames":10},"Triple negative starting any line of therapy, HR+\u002FHER2-, and HER2+ starting ≥2nd line therapy","Subjects will receive CTC enumeration, and CTC HER2, ER, PD-L1 expression minimally before each restaging visit, and cfDNA\u002FRNA assessments at baseline and first restaging as part of standard of care.",[16],{"name":17,"affiliation":18,"role":19},"Marija Balic, MD, PhD, MBA","University of Pittsburgh","PRINCIPAL_INVESTIGATOR",[21,25],{"name":17,"role":22,"phone":23,"phoneExt":10,"email":24},"CONTACT","800-533-8762","balicm@upmc.edu",{"name":26,"role":22,"phone":10,"phoneExt":10,"email":27},"Lisette Stork-Sloots","lstork@medex15.com",[29],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"UPMC Magee Womens Hospital","RECRUITING","Pittsburgh","Pennsylvania","15213","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-79.99589,40.44062,{"lat":41,"lon":40},[44],{"name":17,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100580173","a-study-for-ctc-expression-and-cfdnarna-assessment-in-metastatic-breast-cancer-patients-100580173",false,"NCT06833853","A Study for CTC Expression and cfDNA\u002FRNA Assessment in Metastatic Breast Cancer Patients","CTC-EXPRESS: A Prospective Observational Study for CTC Expression and cfDNA\u002FRNA Assessment in Metastatic Breast Cancer","CTC-EXPRESS","Inclusion Criteria:\n\n* Invasive breast cancer with radiographic and\u002For clinical evidence of advanced metastatic or unresectable disease.\n* HR+\u002FHER2 negative or triple negative (TN) subjects prior to starting first line therapy or beyond in the metastatic setting.\n\nOR HER2+ subjects prior to starting second line therapy or beyond in the metastatic setting.\n\n* Subject must have the CTC HER2, ER, PD-L1, and cfDNA\u002FRNA tests ordered during routine patient care.\n* Age \\> 18 years.\n\nExclusion Criteria:\n\n* Participant is pregnant.\n* Inability to provide blood samples based on the judgment of the treating physician.","ALL","18 Years",{"count":58,"type":59},187,"ESTIMATED","24 Months","OBSERVATIONAL","The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA\u002FRNA (cfDNA\u002FRNA) analysis.",[64],"Metastatic Breast Cancer (MBC)",[66,67,68],"CTC","cfDNA","cfRNA","2026-03-16",{"date":71,"type":72},"2026-03-18","ACTUAL",{"date":74,"type":72},"2026-03-13",{"date":76,"type":59},"2028-10",{"name":5,"class":6},1]